Full-Time
Develops intracellular therapeutics using endosomal escape
$127k - $159k/yr
Boston, MA, USA
Hybrid
Remote option exists but requires regular on-site presence at Boston, MA.
| , |
Entrada Therapeutics focuses on developing a new class of medicines to treat devastating diseases by delivering therapies inside cells. Its core technology, the Endosomal Escape Vehicle (EEV) platform, helps drugs escape from endosomes—cellular compartments that often trap or degrade treatments—so they can reach intracellular targets. The product pipeline centers on EEV-therapeutics, including candidates for Duchenne muscular dystrophy and other neuromuscular diseases, with ENTR-601-45 currently cleared by UK and EU regulators to begin clinical trials. What sets Entrada apart is its explicit emphasis on enabling intracellular delivery to access targets that were previously hard to treat, using a platform-agnostic delivery approach that can work with a range of therapeutics such as oligonucleotides. The company’s goal is to advance multiple EEV-therapeutics through clinical development to address rare and other hard-to-treat diseases and reach patients who need new treatment options.
Company Size
201-500
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
People at Entrada Therapeutics who can refer or advise you
401(k) Company Match
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Stock Options
Company Equity
Wellness Program
Mental Health Support
Gym Membership
Conference Attendance Budget
Professional Development Budget
Phone/Internet Stipend
Home Office Stipend
Entrada Therapeutics to present at upcoming investor conferences. By GlobeNewswire February 4, 2026 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Eastern Time in Boston, MA. Live webcasts will be available on the Investor Relations section of the Company's website at www.entradatx.com. Replays will be available on the Entrada website for 90 days following the events. About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV(TM)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular, ocular and other diseases, leveraging next-generation EEVs, novel oligonucleotide sequences and an advanced protein engineering platform. The Company's lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Investor Contact Karla MacDonald Chief Corporate Affairs Officer Media Contact Megan Prock McGrath CTD Comms, LLC
Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of several exon skipping programs.
Entrada Therapeutics reports Fourth Quarter and Full Year 2024 Financial Results.
MA invests $1.11 million in Entrada Therapeutics, Inc. (NASDAQ:TRDA).